Expression of integrins αvß3 and αvß5 and their ligands in primary and secondary central nervous system neoplasms

Histology and Histopathology

Volumn 28, Issue 6, 2013, Pages 749-758

  Mittelbronn, Michel ^a   Warth, Arne ^b   Meyermann, Richard ^c   Goodman, Simon ^d   Weller, Michael ^e  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d MERCK KGAA   (Germany)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cancer; Integrin expression; Tumour microenvironment

Indexed keywords

ALPHAVBETA5 INTEGRIN; TUMOR MARKER; VITRONECTIN RECEPTOR;

ARTICLE; BRAIN TUMOR; BREAST TUMOR; FEMALE; GLIOBLASTOMA; HUMAN; LUNG TUMOR; MELANOMA; METABOLISM; METASTASIS; PATHOLOGY; SKIN TUMOR;

BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; INTEGRIN ALPHAVBETA3; LUNG NEOPLASMS; MELANOMA; RECEPTORS, VITRONECTIN; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878975000     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Aaboe M., Offersen B.V., Christensen A. and Andreasen P.A. (2003). Vitronectin in human breast carcinomas. Biochim. Biophys. Acta 1638, 72-82.
2. Beauvais D.M., Ell B.J., McWhorter A.R. and Rapraeger A.C. (2009). Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J. Exp. Med. 206, 691-705.
3. Beer A.J., Niemeyer M., Carlsen J., Sarbia M., Nährig J., Watzlowik P., Harbeck N. and Schwaiger M. (2008). Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J. Nucl. Med. 49, 255-59.
4. Bello L., Francolini M., Marthyn P., Zhang J., Carroll R.S., Nikas D.C., Strasser J.F., Villani R., Cheresh D.A. and Black P.M. (2001). Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 49, 380-89.
5. Chen X., Sievers E., Hou Y., Park R., Tohme M., Bart R., Bremner R., Bading J.R. and Conti P.S. (2005). Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia 7, 271-79.
6. Cui R., Takahashi F., Ohashi R., Gu T., Yoshioka M., Nishio K., Ohe Y., Tominaga S., Takagi Y., Sasaki S., Fukuchi Y. and Takahashi K. (2007). Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumour growth of human lung cancer cells in mice. Lung Cancer 57, 302-10.
7. del Zoppo G.J. and Milner R. (2006). Integrin-matrix interactions in the cerebral microvasculature. Arterioscler. Thromb. Vasc. Biol. 26, 1966-1975.
8. Enns A., Korb T., Schlüter K., Gassmann P., Spiegel H.U., Senninger N., Mitjans F. and Haier J. (2005). Alphavbeta5-integrins mediate early steps of metastasis formation. Eur. J. Cancer 41, 1065-1072.
9. Fischer I., Gagner J.P., Law M., Newcomb E.W. and Zagzag D. (2005). Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol. 15, 297-310.
10. Fong Y.C., Liu S.C., Huang C.Y., Li T.M., Hsu S.F., Kao S.T., Tsai F.J., Chen W.C., Chen C.Y. and Tang C.H. (2009). Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 64, 263-270.
11. Gladson C.L. (1996). Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J. Neuropathol. Exp. Neurol. 55, 1143-1149.
12. Gladson C.L. and Cheresh D.A. (1991). Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J. Clin. Invest. 88, 1924-1932.
13. Havaki S., Kouloukoussa M., Amawi K., Drosos Y., Arvanitis L.D., Goutas N., Vlachodimitropoulos D., Vassilaros S.D., Katsantoni E.Z., Voloudakis-Baltatzis I., Aleporou-Marinou V., Kittas C. and Marinos E. (2007). Altered expression pattern of integrin alphavbeta3 correlates with actin cytoskeleton in primary cultures of human breast cancer. Cancer Cell Int. 7, 16.
14. Hodivala-Dilke K. (2008). alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment. Curr. Opin. Cell Biol. 20, 514-519.
15. Hynes R.O. (2002). Integrins: bidirectional, allosteric signaling machines. Cell. 110, 673-687.
16. Jan H.J., Lee C.C., Shih Y.L., Hueng D.Y., Ma H.I., Lai J.H., Wei H.W. and Lee H.M. (2010). Osteopontin regulates human glioma cell invasiveness and tumor growth in mice. Neuro. Oncol. 12, 58-70.
17. Janes S.M. and Watt F.M. (2006). New roles for integrins in squamous-cell carcinoma. Nat. Rev. Cancer 6, 175-183.
18. Kanamori M., Vanden Berg S.R., Bergers G., Berger M.S. and Pieper R.O. (2004). Integrin beta3 overexpression suppresses tumor growth in a human model of gliomagenesis: implications for the role of beta3 overexpression in glioblastoma multiforme. Cancer Res. 64, 2751-2758.
19. Kanamori M., Kawaguchi T., Berger M.S. and Pieper R.O. (2006). Intracranial microenvironment reveals independent opposing functions of host alphaVbeta3 expression on glioma growth and angiogenesis. J. Biol. Chem. 281, 37256-37264.
20. Kim Y.W., Park Y.K., Lee J., Ko S.W. and Yang M.H. (1998). Expression of osteopontin and osteonectin in breast cancer. J. Korean Med. Sci. 13, 652-657.
21. Le Tourneau C., Faivre S. and Raymond E. (2007). The role of integrins in colorectal cancer. Oncology (Williston Park). 21, 21-24.
22. Marshall J.F., Nesbitt S.A., Helfrich M.H., Horton M.A., Polakova K. and Hart I.R. (1991). Integrin expression in human melanoma cell lines: heterogeneity of vitronectin receptor composition and function. Int. J. Cancer 49, 924-931.
23. Matusan-Ilijas K., Behrem S., Jonjic N., Zarkovic K. and Lucin K. (2008). Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma. Pathol. Oncol. Res. 14, 293-298.
24. Maubant S., Saint-Dizier D., Boutillon M., Perron-Sierra F., Casara P.J., Hickman J.A., Tucker G.C. and Van Obberghen-Schilling E. (2006). Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood 108, 3035-3044.
25. Maurer G.D., Tritschler I., Adams B., Tabatabai G., Wick W., Stupp R. and Weller M. (2009). Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol. 11, 747-56.
26. Max R., Gerritsen R.R., Nooijen P.T., Goodman S.L., Sutter A., Keilholz U., Ruiter D.J. and De Waal R.M. (1997). Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int. J. Cancer 71, 320-324.
27. Meyer T., Marshall J.F. and Hart I.R. (1998). Expression of alphav integrins and vitronectin receptor identity in breast cancer cells. Br. J. Cancer 77, 530-536.
28. Mikkelsen T., Brodie C., Finniss S., Berens M.E., Rennert J.L., Nelson K., Lemke N., Brown S.L., Hahn D., Neuteboom D. and Goodman S.L. (2009). Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int. J. Cancer 124, 2719-2727.
29. Moschos S.J., Drogowski L.M., Reppert S.L. and Kirkwood J.M. (2007). Integrins and cancer. Oncology (Williston Park). 21, 13-20.
30. Neto D.S., Pantaleão L., de Sá B.C. and Landman G. (2007). Alpha-vbeta3 integrin expression in melanocytic nevi and cutaneous melanoma. J. Cutan. Pathol. 34, 851-856.
31. Nikolopoulos S.N., Blaikie P., Yoshioka T., Guo W. and Giancotti F.G. (2004). Integrin beta4 signaling promotes tumor angiogenesis. Cancer Cell 6, 471-83.
32. Paulus W., Baur I., Schuppan D. and Roggendorf W. (1993). Characterization of integrin receptors in normal and neoplastic human brain. Am. J. Pathol. 143, 154-163.
33. Reardon D.A., Nabors L.B., Stupp R. and Mikkelsen T. (2008). Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin. Investig. Drugs 17, 1225-1235.
34. Reuning U. (2011). Integrin Rvß3 promotes vitronectin gene expression in human ovarian cancer cells by implicating rel transcription factors. J. Cell Biochem. 112, 1909-1919.
35. Schnell O., Krebs B., Wagner E., Romagna A., Beer A.J., Grau S.J., Thon N., Goetz C., Kretzschmar H.A., Tonn J.C. and Goldbrunner R.H. (2008). Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol. 18, 378-386.
36. Sierko E., Wojtukiewicz M.Z., Zimnoch L., Ostrowska-Cichocka K., Tokajuk P., Ramlau R. and Kisiel W. (2012). Protein Z/protein Zdependent protease inhibitor system in human non-small-cell lung cancer tissue. Thromb. Res. 129, e92-96.
37. Silvestri I., Longanesi Cattani I., Franco P., Pirozzi G., Botti G., Stoppelli M.P. and Carriero M.V. (2002). Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating alpha(v)beta5 vitronectin receptor cell surface expression. Int. J. Cancer 102, 562-571.
38. Somanath P.R., Malinin N.L. and Byzova T.V. (2009). Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis 12, 177-185.
39. Sreekanthreddy P., Srinivasan H., Kumar D.M., Nijaguna M.B., Sridevi S., Vrinda M., Arivazhagan A., Balasubramaniam A., Hegde A.S., Chandramouli B.A., Santosh V., Rao M.R., Kondaiah P. and Somasundaram K. (2010). Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol. Biomarkers Prev. 19, 1409-22.
40. Streuli C.H. (2009). Integrins and cell-fate determination. J. Cell Sci. 122, 171-177.
41. Stupp R., Hegi M.E., Neyns B., Goldbrunner R., Schlegel U., Clement P.M., Grabenbauer G.G., Ochsenbein A.F., Simon M., Dietrich P.Y., Pietsch T., Hicking C., Tonn J.C., Diserens A.C., Pica A., Hermisson M., Krueger S., Picard M. and Weller M. (2010). Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 2712-2718.
42. Taherian A., Li X., Liu Y. and Haas T.A. (2011). Differences in integrin expression and signaling within human breast cancer cells. BMC Cancer 11, 293.
43. Tzukert K., Shimony N., Krasny L., Urieli-Shoval S., Gorodetsky R., Avrahami I., Nettelbeck D.M. and Haviv Y.S. (2010). Human melanoma cells expressing the alphavbeta3 integrin are partially protected from necrotic cell death induced by dynamic matrix detachment. Cancer Lett. 290, 174-81.
44. Varner J.A. and Cheresh D.A. (1996). Integrins and cancer. Curr. Opin. Cell Biol. 8, 724-30.
45. Vellon L., Menendez J.A., Liu H. and Lupu R. (2007). Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner. Differentiation 75, 819-30.
46. Verbisck N.V., Costa E.T., Costa F.F., Cavalher F.P., Costa M.D., Muras A., Paixão V.A., Moura R., Granato M.F., Ierardi D.F., Machado T., Melo F., Ribeiro K.B., Cunha I.W., Lima V.C., Maciel Mdo S., Carvalho A.L., Soares F.F., Zanata S., Sogayar M.C., Chammas R. and Camargo A.A. (2009). ADAM23 negatively modulates alpha(v)beta(3) integrin activation during metastasis. Cancer Res. 69, 5546-5552.
47. Zámecník J., Vargová L., Homola A., Kodet R. and Syková E. (2004). Extracellular matrix glycoproteins and diffusion barriers in human astrocytic tumours. Neuropathol. Appl. Neurobiol. 30, 338-350.